{
    "nct_id": "NCT06075953",
    "official_title": "DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study",
    "inclusion_criteria": "* Female, at least 18 years old\n* previous diagnosis of Hormone Receptor positive (HR+) DCIS (at least 50% ER or PR and 2+; biopsy will have been performed previously at diagnosis) with or without microinvasion\n* Informed consent provided by the patient\n* Willingness and ability to provide tumor samples for research\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or actively breastfeeding women (must be documented by a pregnancy test during screening)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history.\n* Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer\n* Co-enrollment in clinical trials of pharmacologic agents requiring an Investigational new Drug Appilcation (IND)\n* Ongoing treatment for DCIS other than what is specified in this protocol\n* Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements.\n* Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Participants unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance to oral treatment. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures.",
    "miscellaneous_criteria": ""
}